SGLT2 inhibition and inflammasome pathway and diabetic nephropathy
Abstract
This study investigated the effects of sodium glucose cotransport 2 (SGLT2) inhibition on cardiac redox homeostasis and inflammation in an experimental model of DN. Male C57BL/6J mice were fed either standard chow (SC) or high-fat diet (HFD) for 16 weeks, with the HFD animals receiving streptozotocin (40 mg/kg) at week 8. At week 17, mice were divided into four groups: Sham, Sham+SGLT2i, DN, and DN+SGLT2i (empagliflozin 35 mg/kg for 8 weeks), and their cardiac tissues were analyzed for oxidative stress markers and inflammatory mediators.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.